ECHTA - PRINCETON, NJ--(BUSINESS WIRE)--Sept. 23, 1999--EchoCath, Inc.
(NASD-OTC:ECHTA) announced today it has been granted permission by the
U.S. Food and Drug Administration to market its EchoFlow(TM) Blood
Velocity Meter System (BVM-1). EchoFlow BVM is an angle-independent
blood velocity measuring system that enables physicians to evaluate
and quantify blood flow in vessels using ultrasound technology. Blood
velocity is an important parameter of circulatory system health.
The initial clinical uses for the system are being explored by
Dr. Larry Hollier of The Mt. Sinai Medical Center, New York, NY, who
remarked "The EchoFlow system is an easy-to-use, cost-effective method
of assessing the condition of blood vessels during surgery. It will be
a useful tool in assessing proper placement of bypass grafts and in
measuring improvement of vessel performance in the intra-operative and
post-operative setting."
EchoCath President Frank DeBernardis commented " EchoFlow is a
platform technology that will have numerous important clinical uses,
including monitoring blood flow for implantable devices, such as
pacemakers, and catheter-based flow measurement for angioplasty and
cardiac output measurement. The present system, the first to
incorporate EchoFlow technology, has been cleared for marketing to
measure blood flow velocities of vessels intra-operatively or below
the skin." DeBernardis added, "EchoCath is focused on preparing for
full commercialization of this first application, targeting vascular
surgeons for use in peripheral vascular surgery. Simultaneously, we
are seeking corporate alliances for applications beyond vascular
surgery."
Certain statements herein constitute "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation statements regarding acceptability
by vascular surgeons of the Company's technology, the ability to
receive FDA 510 (k) approvals for other applications and securing
corporate alliances. |
